利培酮合并奥卡西平治疗精神分裂症兴奋躁动的比较研究

The comparative study of Risperidone combined with Oxcarbazepine in the treatment of excited restlessness schizophrenia patients

目的:评估奥卡西平辅助治疗兴奋躁动精神分裂症的疗效和安全性。方法:将符合中国精神障碍分类与诊断标准第3版中精神分裂症诊断标准并以兴奋躁动为主要表现的68例患者随机分为研究组(n=35)和对照组(n=33),研究组应用抗精神病药物利培酮联合奥卡西平,对照组单一使用利培酮,观察6周。采用简明精神病量表(BPRS)和阳性与阴性症状量表(PANSS)兴奋因子、临床疗效总印象量表(CGI)、不良反应量表(TESS)在治疗前及治疗后第1、2、4周分别评估疗效和安全性。结果:研究组有效29例(82.9%),对照组有效19例(57.6%),两组有效率比较差异有统计学意义(χ2=5.229,P<0.05)。研究组与对照组患者分别脱落1例和2例。研究组的主要不良反应为镇静(9例)、便秘(9例)、头晕(7例)、心动过速(6例)等,对照组的主要不良反应为便秘(11例)、口干(10例)、心动过速(7例)、锥体外系不良反应(6例)等。结论:奥卡西平能有效辅助治疗精神分裂症的兴奋状态。

Objective：To evaluate the efficacy and safety of Risperidone combined with Oxcarbazepine in the treatment of excited restlessness schizophrenia patients. Methods ：68 excited restlessness patients with schizophrenia were randomly divided into study group（ n = 35 ） and control group（ n = 33 ）, study group used Risperidone combined with Oxcarbazepine, control group only used Risperidone, treatment for 6 weeks. Using the Brief Psychiatric Rating Scale （BPRS） and the positive and Negative Syndrome Scale （PANSS） excitation factor, Clinical Global Impression Scale （CGI）, adverse effect scale （TESS） to evaluate the efficacy and safety respectively before treatment and 1,2,4 week after treatment. The effective rate of study group was 57.6 % （ 29 cases）, the effective rate of control group was 57.6% （ 19 cases）, there was statistical difference （ X2 = 5. 229, P 〈 0.05 ）. The study group and the control group were off one cases and two cases. The main adverse reactions of study group were sedation （9 cases）, constipation （9 cases）, dizziness （ 7 cases ）, tachycardia （ 6 cases ） ; the main adverse reactions of control group were constipation （ 11 cases）, dry mouth （ 10 cases）, tachycardia （ 7 cases）, extrapyramidal adverse （6 cases）. Conclusion：Oxcarbazepine can effective secondary treatment of schizophrenia excited state.